Clinical Trials Browser

INDUSTRY × Surgical Procedures, Operative × 1 year × Clear all

Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Phase 3 Completed

200 enrolled 16 charts

Breast

HER2-positive Early Breast Cancer

NCT05415215 2026-02-10

ProHer

Phase 3 Completed

346 enrolled 20 charts

Breast

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

808 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Breast

Triple Negative Breast Neoplasms

NCT03567889 2025-12-17

NeoDREAM

Phase 3 Recruiting

186 enrolled

Dermatologic

Melanoma

NCT06295809 2025-12-09

INTerpath-007

Phase 2/3 Active not recruiting

46 enrolled

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

NCT03924856 2025-08-28

KEYNOTE-866

Phase 3 Active not recruiting

907 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03725059 2025-07-11

KEYNOTE-756

Phase 3 Active not recruiting

1,240 enrolled

Breast

Breast Neoplasms

NCT03800134 2025-06-11

AEGEAN

Phase 3 Active not recruiting

825 enrolled 1 FDA

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Clinical Trials

IL Believe

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

ProHer

KEYNOTE-B15

neoMono

NeoDREAM

INTerpath-007

KEYNOTE-866

KEYNOTE-756

AEGEAN